Program Compounds Clause Samples
The 'Program Compounds' clause defines the rules and requirements regarding chemical compounds that are developed or identified within the scope of a specific research or development program. Typically, this clause outlines which compounds qualify as 'Program Compounds,' how they are documented, and the ownership or rights associated with them. For example, it may specify that any new molecules synthesized during a collaboration are considered Program Compounds and detail how they are reported to the other party. The core function of this clause is to clearly establish which compounds are covered by the agreement, thereby preventing disputes over intellectual property and ensuring both parties understand their rights and obligations regarding these compounds.
Program Compounds. Within [***] business days of the end of each calendar quarter (ending each March 31, June 30, September 30 and December 31) during the Research Term ARCHEMIX will notify EYETECH and the JRC of each Program Compound identified in such calendar quarter.
Program Compounds. Notwithstanding the exclusion of one or more indications from the Field for the Tier 1 Program, the Tier 2 Program or any Tier 3 Program (each, an “Excluded Indication”), if, prior to the third (3rd) anniversary of the Amendment Date, Roche proposes to grant to any Third Party any license or other right to develop or commercialize any Program Compound for the Tier 1 Program, the Tier 2 Program or any Tier 3 Program for any Excluded Indication in the Territory, or for any indication outside the Field in the Territory, then, promptly after reaching agreement in principle with such Third Party regarding the material terms upon which Roche would grant such license or right (the “Third Party Terms”) but before entering into any definitive agreement with such Third Party, Roche shall notify Synosia in writing of the Third Party Terms. During the sixty (60)-day period following ▇▇▇▇▇▇▇’s receipt of the Third Party Terms, Roche shall, and it hereby does, grant to Synosia an exclusive right of first refusal to obtain such license or right on the Third Party Terms. If Synosia wishes to exercise such right of first refusal, then upon Synosia’s written notification to Roche given at any time prior to the expiration of such sixty (60)-day period, the parties shall use their best efforts to enter into a definitive agreement on the Third Party Terms as promptly as practicable thereafter. If Synosia fails to exercise its right of first refusal by the expiration of such sixty (60)-day period, or if Synosia exercises such right but the parties fail to enter into a definitive agreement within four (4) months after such exercise, then Roche shall be free to grant such license or right to the Third Party on terms no more favorable to such Third Party than the Third Party Terms. In addition, if, on or after the third (3rd) anniversary of the Amendment Date and prior to the sixth (6th) anniversary of the Amendment Date, Roche proposes to grant any license or other right to develop or commercialize, any Program Compound for the Tier 1 Program, the Tier 2 Program or any Tier 3 Program for any Excluded Indication in the Territory, then Roche shall, prior to initiating negotiations with such Third Party with respect thereto, provide written notice of such intent to Synosia, which notice shall identify the applicable Program Compound and Excluded Indication(s) for which Roche proposes to grant such rights. During the sixty (60)-day period following the date Roche delivers such notice...
Program Compounds. Amgen shall pay Tularik the following amounts within [**] after the occurrence of the corresponding milestone events. Each payment under this Section 8.3.1 shall be made only once per Target, for the first Program Compound directed against each particular Program Target (or the first Back-Up Compound directed against such Program Target) for which such milestone is achieved, except as provided below. [**] [**] Commencement of first Phase I Study [**] Start of first Phase IIB Study [**] Commencement of first Phase IIIA Study [**] First NDA filing [**] First Commercial Sale in Europe [**] First Commercial Sale in the United States [**] First Commercial Sale in Japan [**] [**]